Treatment patterns, biomarker testing, and outcomes in patients with nonsquamous non-small cell lung cancer (NSCLC) receiving second-line treatment in the US Oncology network.
IWen Pan
No relevant relationships to disclose
Rajiv Mallick
Employment or Leadership Position - Daiichi Sankyo
Stock Ownership - Daiichi Sankyo
Rahul Dhanda
No relevant relationships to disclose
Eric S. Nadler
Consultant or Advisory Role - Genentech (U); Lilly (U); Pfizer (U)
Honoraria - Genentech; Lilly; Pfizer